Extreme FDA Trades: 30 Stocks Under 5 Bucks [View article]
intranasal ketamine? really? Thanks for this info, this is interesting. I had no idea anyone was developing ketamine for this purpose.
For anyone interested, check out this link about DM Turner, a "psychonautic researcher" who drowned in his bathtub while tripping on "Special K." He was hooked on the stuff for many years.
> Check out this good, recent update article for JAV: > seekingalpha.com/artic... > > > JAV also mentioned above in my extreme trade article for pending > Ereska Phase 3 results: > > Ereska is a non-opiate pain drug being developed by (1) Javelin Pharma > (AMEX:seekingalpha.com/symbo...)($1.90) for the acute treatment > of moderate to severe pain in military, trauma, post-operative, and > emergency room settings with the potential for treating breakthrough > pain from cancer as well. The drug is delivered by a disposable manual > pump with a rapid onset and duration of pain relief of about two > hours without opiate side effects such as respiratory depression. > JAV expects to release the primary endpoint data from the Ereska > (intranasal ketamine) Phase 3 pivotal trial in mid-2009, which consists > of 220 adult patients to evaluate the safety and effectiveness of > the drug in the treatment of acute pain (arising from surgery, trauma, > or injury).
Extreme FDA Trades: 30 Stocks Under 5 Bucks [View article]
For anyone interested, check out this link about DM Turner, a "psychonautic researcher" who drowned in his bathtub while tripping on "Special K." He was hooked on the stuff for many years.
www.erowid.org/culture...
On Aug 10 01:06 PM Mike Havrilla wrote:
> Check out this good, recent update article for JAV:
> seekingalpha.com/artic...
>
>
> JAV also mentioned above in my extreme trade article for pending
> Ereska Phase 3 results:
>
> Ereska is a non-opiate pain drug being developed by (1) Javelin Pharma
> (AMEX:seekingalpha.com/symbo...)($1.90) for the acute treatment
> of moderate to severe pain in military, trauma, post-operative, and
> emergency room settings with the potential for treating breakthrough
> pain from cancer as well. The drug is delivered by a disposable manual
> pump with a rapid onset and duration of pain relief of about two
> hours without opiate side effects such as respiratory depression.
> JAV expects to release the primary endpoint data from the Ereska
> (intranasal ketamine) Phase 3 pivotal trial in mid-2009, which consists
> of 220 adult patients to evaluate the safety and effectiveness of
> the drug in the treatment of acute pain (arising from surgery, trauma,
> or injury).